WuXi AppTec CDMO STA Pharma inks exclusive deal with Swiss biotech BioLingus

Pills Getty
STA Pharmaceutical has signed an exclusive tech and marketing deal with Swiss biotech BioLingus for sublingual delivery of drugs. (Getty)

WuXi AppTec’s CDMO subsidiary STA Pharmaceutical has signed an exclusive tech and marketing deal with Swiss biotech BioLingus for sublingual delivery of drugs.

As part of the collaboration, WuXi STA will get exclusive access to BioLingus’ technology for sublingual and buccal delivery in the CDMO arena. The Swiss biotech’s technology centers on a platform that stabilizes and delivers sublingually—either orally or under the tongue—drug targets that include small molecules, peptides and proteins that are currently given to patients through IV.

“WuXi STA is one of the world leaders in this field, with an integrated CMC platform from preclinical development to commercialization,” Yves Decadt, chief executive for BioLingus, said in a statement. “This partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

WuXi STA’s chief executive, Minzhang Chen, added that the partnership will offer more economical convenient and effective delivery solutions for patients across the globe.

Last year, the CDMO opened a new R&D center in Shanghai, right next to its production plant. WuXi STA boasts more than 1,000 scientists at five locations in China and the U.S. Globally, WuXi AppTec has more than 18,000 employees at more than two dozen facilities.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.